NewsBenzingaADMA Biologics: EPS rettificato del terzo trimestre a 0,23 dollari supera la stima di 0,20 dollari; ricavi a 141,102 milioni di dollari superano la stima di 138,190 milioni di dollari ADMA Biologics: EPS rettificato del terzo trimestre a 0,23 dollari supera la stima di 0,20 dollari; ricavi a 141,102 milioni di dollari superano la stima di 138,190 milioni di dollari Benzinga 2026.11.04 21:17 (GMT+0) Open on Benzinga Other news Israeli Shipping Giant ZIM Cashes In on Surging Freight Rates, Raises Outlook UBS Maintains Buy on Home Depot, Lowers Price Target to $417 Disney Posts Upbeat Q4, Analysts Raise Price Target Citing Theme Park Resilience StoneX Maintains Buy on Bitdeer Techs, Lowers Price Target to $15 Merck Pulls Plug On Acquired Drug after Safety Review UBS Maintains Neutral on Granite Point Mortgage Tr, Lowers Price Target to $3